Abstract
Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimers disease (AD) in Europe on 17th May 2002 and shortly thereafter was also approved by the FDA for use in the same indication in the USA. Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with strong voltage-dependency and fast kinetics. Due to this mechanism of action (MOA), there is a wealth of other possible therapeutic indications for memantine and numerous preclinical data in animal models support this assumption. This review is intended to provide an update on preclinical studies on the pharmacodynamics of memantine, with an additional focus on animal models of diseases aside from the approved indication. For most studies prior to 1999, the reader is referred to a previous review [196]. In general, since 1999, considerable additional preclinical evidence has accumulated supporting the use of memantine in AD (both symptomatic and neuroprotective). In addition, there has been further confirmation of the MOA of memantine as an uncompetitive NMDA receptor antagonist and essentially no data contradicting our understanding of the benign side effect profile of memantine.
Current Neuropharmacology
Title: Pharmacodynamics of Memantine: An Update
Volume: 6 Issue: 1
Author(s): C. G. Parsons, G. Rammes and W. Danysz
Affiliation:
Abstract: Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimers disease (AD) in Europe on 17th May 2002 and shortly thereafter was also approved by the FDA for use in the same indication in the USA. Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with strong voltage-dependency and fast kinetics. Due to this mechanism of action (MOA), there is a wealth of other possible therapeutic indications for memantine and numerous preclinical data in animal models support this assumption. This review is intended to provide an update on preclinical studies on the pharmacodynamics of memantine, with an additional focus on animal models of diseases aside from the approved indication. For most studies prior to 1999, the reader is referred to a previous review [196]. In general, since 1999, considerable additional preclinical evidence has accumulated supporting the use of memantine in AD (both symptomatic and neuroprotective). In addition, there has been further confirmation of the MOA of memantine as an uncompetitive NMDA receptor antagonist and essentially no data contradicting our understanding of the benign side effect profile of memantine.
Export Options
About this article
Cite this article as:
Parsons G. C., Rammes G. and Danysz W., Pharmacodynamics of Memantine: An Update, Current Neuropharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157015908783769671
DOI https://dx.doi.org/10.2174/157015908783769671 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design Reduction of Myocardial Ischemia-Reperfusion Injury with Pre- and Postconditioning: Molecular Mechanisms and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
Current Pharmaceutical Design The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Current Medicinal Chemistry Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Intra- and Interdomain Flexibility in Matrix Metalloproteinases: Functional Aspects and Drug Design
Current Pharmaceutical Design Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Editorial [ Pharmacological Modulation of Liver Ischemia - Reperfusion Injury Executive Editors: G.K. Glantzounis, D.P. Mikhailidis, A.M. Seifalian and B.R. Davidson ]
Current Pharmaceutical Design Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) α2-Antiplasmin on Cardiovascular Diseases
Current Pharmaceutical Design